Q32 Bio Logo (PRNewsfoto/Q32 Bio) "We have conviction that bempikibart is differentiated from existing AA therapies and has the potential to transform the treatment paradigm for this disease. This is ...

Logo (PRNewsfoto/TransCode Therapeutics, Inc.) Several patients ... a microRNA widely believed to be critical to the emergence and progression of many metastatic cancers. TransCode's 2023 Phase ...

Logo (PRNewsfoto/TransCode Therapeutics, Inc.) Several patients in the first ... a microRNA widely believed to be critical to the emergence and progression of many metastatic cancers. TransCode's 2023 ...

As Elon Musk moves to shutter the U.S. Agency for International Development, the agency’s support for the discovery of novel ...

The FDA recently granted EXG-34217 Rare Pediatric Disease Designation (RPDD) and Regenerative Medicine Advanced Therapy (RMAT) Designation.

Under the terms of the agreement, TG Therapeutics obtains non-exclusive research, clinical and commercial rights to use MaxCyte's Flow Electroporation ® technology and ExPERT ™ platform.

In a report released today, Joon Lee from Truist Financial maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report). The company’s shares closed yesterday at $7.16. Leverage the ...

Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced that the U.S ...

RESEARCH TRIANGLE PARK, N.C., Feb. 14, 2025 /PRNewswire/ -- Dignify Therapeutics, a biotechnology company dedicated to restoring voluntary bowel and bladder function in patients with neurological ...

TTX-MC138 is a first-in-class therapeutic candidate designed to inhibit microRNA-10b, or miR-10b, a microRNA widely believed to be critical to the emergence and progression of many metastatic cancers.